B37.89 Other sites of candidiasis

Name of the Condition

• Other Sites of Candidiasis (ICD Code: B37.89)
• Technical term: Other sites of candidiasis
• ICD-10 Code: B37.89

Summary

Other sites of candidiasis is a fungal infection caused by Candida species, affecting body areas not classified under more specific Candidiasis subtypes. It occurs when Candida, a normally present yeast, overgrows in localized or systemic sites, leading to inflammation and tissue involvement. The condition may present as superficial or invasive, depending on the site and host factors.

Causes

Other sites of candidiasis results from the overgrowth of Candida fungi, which are part of the normal microbial flora. This overgrowth can be triggered by disruptions to the body's natural balance, such as antibiotic use, hormonal changes, or weakened immune function. Invasive forms may arise from hematogenous spread or direct inoculation into non-mucosal sites.

Risk Factors

• Weakened immune system (e.g., HIV/AIDS, chemotherapy, immunosuppressive therapy).
• Prolonged use of broad-spectrum antibiotics or corticosteroids.
• Diabetes mellitus or poorly controlled blood sugar.
• Invasive medical procedures or indwelling devices.
• Chronic skin conditions or moisture-related skin breakdown.
• Malnutrition or systemic illness.

Symptoms

• Localized redness, swelling, or discharge at the affected site.
• Pain, itching, or discomfort.
• Ulceration or tissue breakdown in severe cases.
• Systemic symptoms (e.g., fever, fatigue) if infection spreads.

Diagnosis

Diagnosis involves clinical evaluation of symptoms and affected sites, often supported by laboratory testing. Direct microscopy or culture of samples from the affected area may identify Candida species. Biopsy or imaging may be used to assess tissue involvement or rule out other conditions, particularly in invasive cases.

Treatment Options

Treatment depends on the site and severity of infection. Superficial infections may respond to topical antifungal agents, while systemic or invasive cases require oral or intravenous antifungal medications. Underlying risk factors, such as immune suppression or diabetes, should be addressed to prevent recurrence.

Prognosis and Follow-Up

Prognosis varies based on the site, severity, and host factors. Superficial infections typically resolve with treatment, but invasive or widespread candidiasis may have a more guarded outlook, especially in immunocompromised individuals. Follow-up may include monitoring for recurrence or complications, particularly in high-risk patients.

Complications

• Spread of infection to other body sites or bloodstream (candidemia).
• Tissue damage or scarring at the affected site.
• Chronic or recurrent infections in immunocompromised patients.
• Systemic inflammatory response in severe cases.

Lifestyle & Prevention

• Maintain good hygiene and keep skin dry to reduce moisture-related risk.
• Manage underlying conditions like diabetes or immune disorders.
• Use antibiotics or corticosteroids only as prescribed to avoid disrupting microbial balance.
• Seek prompt treatment for skin breaks or wounds to prevent infection.

When to Seek Professional Help

Consult a healthcare provider if symptoms persist, worsen, or involve systemic signs (e.g., fever, fatigue). Seek immediate care for severe pain, spreading redness, or signs of infection in high-risk individuals.

Tips for Medical Coders

Document the specific site of candidiasis (e.g., skin, bone, or other non-specified areas) to support accurate coding. Ensure clinical details align with the diagnosis, as B37.89 is used when the site is not classified under more specific Candidiasis subtypes. Verify that the code reflects the documented location and severity of infection.